2型糖尿病の処方を最適化するために,日常的に利用可能な臨床特性を用いた5種類の薬剤クラスモデル:予測モデル開発と検証研究

John M Dennis¹, Katherine G Young¹, Pedro Cardoso¹

¹Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.

Lancet (London, England)

|February 28, 2025

まとめ

新しいモデルは,通常の臨床データを用いて2型糖尿病の最適な低血糖薬を予測します. 予想された最適な治療を受けた患者は,HbA1cの改善と合併症のリスクの減少を示した.

科学分野:

内分泌学と代謝
ファルマゲノミクスとパーソナライズド医療
糖尿病の治療と治療

背景:

2型糖尿病 (T2D) の個別化治療の選択には,血糖値を下げる薬の相対的な有効性に関する確固たるデータがない.
T2Dにおける患者特有の治療反応を予測するために,通常の臨床特徴は十分に活用されていない.

研究の目的:

T2Dにおける5つの一般的な血糖低下薬の相対的な有効性を予測するモデルを開発し,検証する.
T2D患者の最適の低血糖治療の選択に,通常利用可能な臨床的特徴が役立つかどうかを評価する.

主な方法:

観察データ (CPRD) とランダム化試験を用いて,5つの薬剤クラスモデルが開発され,検証された.
このモデルは,通常利用可能な9つの臨床特徴 (年齢,糖尿病の持続時間,性別,HbA1c,BMI,eGFR,HDL,総コレステロール,ALT) を含む.
モデル性能は,予測されたHbA1c減少と観察されたHbA1c減少を比較し,長期的な臨床結果を評価することによって評価された.

主要な成果:

このモデルは,異なるデータセットにおける血糖学的有効性を正確に予測した.
モデルで予測された最適な治療を受けた個人は,不調和の群と比較してHbA1cの減少が大きい (5. 3 mmol/ mol).
モデルコンコードント治療は,血糖不全,MACE- HF,腎臓進行,および微血管合併症のリスクを低下させた.

結論:

通常の臨床データを用いて検証されたモデルは,T2D患者の最適の血糖低下治療法を特定できます.
モデルに基づくパーソナライズされた治療法は,血糖制御を改善し,糖尿病の合併症リスクを軽減します.
モデルが共通のパラメータに依存しているため,グローバル臨床実践への統合が容易になります.

さらに関連する動画

10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

関連する概念動画

01:15

Diabetes: Management and Pharmacotherapy

227

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

227

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

151

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

151

01:23

Dipeptidyl Peptidase 4 Inhibitors

161

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

161

01:24

Glucagon-like Receptor Agonists

290

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

290

01:16

Insulin: Dosing Regimen and Adverse Effects

137

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

137

01:23

Antidepressant Drugs: MAOIs and Other Agents

175

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

175

関連する実験動画